NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
NOVARTIS AG
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026
$150.20−0.42 (-0.28%)
Close on Oct 19, 2026
- Market cap
- $287.48B
- P/E (TTM)
- 21.0
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Gross profit | +10.5% | +10.5% | +4.3% | +2.7% | |
| Operating income | +21.3% | +30.5% | +11.7% | +7.0% | |
| Net income | +17.1% | +26.2% | +11.6% | -2.4% | |
| EPS, diluted | +21.8% | +31.1% | +15.2% | -0.2% | |
| Free cash flow | +8.3% | +9.7% | +7.3% | +6.3% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 14.4% | 31.0% | |
| Return on assets | – | 6.6% | 13.1% | |
| Current ratio | 1.12 | 0.90 | 1.12 | |
| Interest coverage | 11.7× | 11.7× | 15.4× | |
| Diluted shares | 2.40B | 2.30B | 1.96B |
Where the cash went
Fiscal 2021 to 2025, five years combined
Novartis generated $80.53B from operations and spent $83.50B on capital expenditure, dividends and share buybacks. 7% of that went back into the business.
Generated
$80.53B
Used
$83.50B
Capital expenditure$5.96B7%Dividends$37.57B45%Share buybacks$39.97B48%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$13.98B
- Cash generatingOperating cash flow above zero$19.14B
- Return on assets improvedROA up on the prior year11.9% → 13.7%
- Earnings backed by cashOperating cash flow above net income$19.14B vs $13.98B
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.04 → 1.12
- No dilutionShare count did not rise2.04B → 1.96B
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –